Prescription, dispensation and marketing patterns of methylphenidate

Revista de Saude Publica

Volumn 48, Issue 6, 2014, Pages 873-880

  Perini, Edson ^a   Junqueira, Daniela Rezende Garcia ^b   Lana, Lorena Gomes Cunha ^a   Luz, Tatiana Chama Borges ^c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SYDNEY   (Australia)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Drug utilization; Drugs of special control; Methylphenidate, administration dosage.; Pharmacoepidemiology; Psychotropic drugs

Indexed keywords

METHYLPHENIDATE; PSYCHOTROPIC AGENT;

BRAZIL; CROSS-SECTIONAL STUDY; DRUG LEGISLATION; ECONOMICS; FEMALE; HUMAN; MALE; PHARMACY; PRESCRIPTION; SOCIOECONOMICS; STANDARDS; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL;

BRAZIL; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; LEGISLATION, DRUG; MALE; METHYLPHENIDATE; MODELS, THEORETICAL; PHARMACEUTICAL SERVICES; PSYCHOTROPIC DRUGS; SOCIOECONOMIC FACTORS;

EID: 84921483997     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0034-8910.2014048005234     Document Type: Article

References (25)

1. Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV. Advances in understanding and treating ADHD. BMC Med. 2011;9:72. DOI:10.1186/1741-7015-9-72
2. Batstra L, Frances A. DSM-5 further inflates attention deficit hyperactivity disorder. J Nerv Ment Dis. 2012;200 (6):486-8. DOI:10.1097/NMD.0b013e318257c4b6
3. Bor W, Heath F, Heussler H, Reuter R, Perrett C, Lee E. Can a multi-disciplinary assessment approach improve outcomes for children with attention deficit hyperactivity disorder? Australas Psychiatry. 2013;21 (5):499-503. DOI:10.1177/1039856213497524
4. Carlini EA, Nappo SA, Nogueira V, Naylor FGM. Metilfenidato: influência da notificação de receita A (cor amarela) sobre a prática de prescrição por médicos brasileiros. Rev Psiquiatr Clin. 2003;30 (1):11-20. DOI:10.1590/S0101-60832003000100002
5. Cox ER, Motheral BR, Henderson RR, Mager D. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics. 2003;111 (2):237-43. DOI:10.1542/peds.111.2.237
6. Dopheide JA. The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. Am J Manag Care. 2009;15 (5 Suppl):S141-50.
7. Dupont RL, Coleman JJ, Bucher RH, Wilford BB. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict. 2008;17 (3):167-71. DOI:10.1080/10550490802019642
8. Griggins C. Dosing dilemmas: are you rich and white or poor and black? Am J Bioeth. 2005;5 (3):55-7. DOI:10.1080/15265160591002782
9. Gumy C, Huissoud T, Dubois-Arber F. Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics. J Atten Disord. 2010; 14 (3):267-72. DOI:10.1177/1087054709356386
10. Hallas J. Drug utilization statistics for individual-level pharmacy dispensing data. Pharmacoepidemiol Drug Saf. 2005;14 (7):455-63. DOI:10.1002/pds.1063
11. Hallas J, Stovring H. Templates for analysis of individual-level prescription data. Basic Clin Pharmacol Toxicol. 2006;98 (3):260-5. DOI:10.1111/j.1742-7843.2006.pto_257.x
12. Hodgkins P, Sasané R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther. 2011;33 (2):188-203. DOI:10.1016/j.clinthera.2011.03.001
13. Hodgson K, Hutchinson AD, Denson L. Nonpharmacological treatments for ADHD: a meta-analytic review. J Atten Disord. 2014;18 (4):275-82. DOI:10.1177/1087054712444732
14. Leonard BE, McCartan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol. 2004;19 (3):151-80. DOI:10.1002/hup.579
15. Miller AR, Lalonde CE, McGrail KM, Armstrong RW. Prescription of methylphenidate to children and youth, 1990-1996. CMAJ. 2001; 165 (11):1489-94.
16. Morton WA, Stockton GG. Methylphenidate abuse and psychiatric side effects. Prim Care Companion J Clin Psychiatry. 2000;2 (5):159-64. DOI:10.4088/PCC.v02n0502
17. Novak SP, Kroutil LA, Williams RL, Van Brunt DL. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy. 2007;2:32. DOI:10.1186/1747-597X-2-32
18. Polanczyk G, Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164 (6):942-8. DOI:10.1176/appi.ajp.164.6.942
19. Pottegard A, Bjerregaard BK, Glintborg D, Hallas J, Moreno SI. The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective. Eur J Clin Pharmacol. 2012;68 (10):1443-50. DOI:10.1007/s00228-012-1265-y
20. Rey JM, Sawyer MG. Are psychostimulant drugs being used appropriately to treat child and adolescent disorders? Br J Psychiatry. 2003;182 (4):284-6. DOI:10.1192/bjp.02.61
21. Schubert I, Köster I, Lehmkuhl G. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007. Dtsch Arztebl Int. 2010; 107 (36):615-21. DOI:10.3238/arztebl.2010.0615
22. Strom BL, Kimmel SE, editors. Textbook of pharmacoepidemiology. 4.ed. Hoboken: John Wiley & Sons; 2006.
23. Truter I. Methylphenidate: prescribing patterns in a South African primary care patient population. J Clin Pharm Ther. 2005;30 (1):59-63. DOI:10.1111/j.1365-2710.2004.00608.x
24. Truter I. Prescribing of methylphenidate to children and adolescents in South Africa: a pharmacoepidemiological investigation. SA Fam Prac. 2009;51 (5):413-7.
25. Vance A. A current treatment approach for attention deficit hyperactivity disorder. Aust Prescr. 2008;31 (5):129-32.